Shares of consumer health company Kenvue ($KVUE) have plunged following the Trump administration’s announcement that Tylenol use during pregnancy ...

UBS lowered the firm’s price target on Kenvue (KVUE) to $17 from $23 and keeps a Neutral rating on the shares. The firm sees another “dynamic” ...

If you are trying to figure out whether to hold onto your Kenvue shares, add more to your portfolio, or sit this one out, you are definitely not alone. Investors have watched Kenvue’s stock price take ...

Tylenol, a popular over-the-counter pain reliever whose active ingredient is acetaminophen, is made by Kenvue, a spinoff of ...

Shares may be rising because investors expected the White House to announce stricter regulations on the medication, Citi ...

Globe Investor value reports provide a daily price target for more than 9,000 stocks on the TSX, Nasdaq, and NYSE. Used by Bay Street pros, advisors and Canadians who invest on their own, they help ...

While Kenvue's Tylenol has attracted intense political pressure, speculators are determined to make KVUE stock great again.

Shares of Tylenol maker Kenvue dropped Monday ahead of an anticipated announcement by the Trump administration linking ...

The review is intended to “reduce complexity, improve execution and accelerate growth,” says a company spokesperson.

Kenvue faces legal and macro risks but offers income potential with a 5% yield and strategic focus on core brands. Read why ...

Kenvue shares declined on Tylenol autism reports, creating a long-term buying opportunity for savvy investors. Click here to ...

President Donald Trump created a potentially existential crisis for Tylenol maker Kenvue Inc. with just three words about the ...